Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
WakeMed, a three-hospital system in the North Carolina capital region of Raleigh, would become part of Advocate Health, Atrium’s parent company, if the deal goes through. Advocate is one of the largest not-for-profit health systems in the U.S.
The New Jersey-based drug developer joins AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer in offering products directly to patients at a discounted rate. Johnson & Johnson is currently listing four medications on the platform.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.
Federal regulators alleged that U.S. Anesthesia Partners—a portfolio company of Welsh, Carson, Anderson & Stowes—engaged in a “roll-up scheme” in Texas that effectively eliminated the competition. The company denies the allegations, but has agreed to undisclosed terms that would see the lawsuit resolved.
A Silicon Valley AI shop has been OK’d by the FDA to market software that automatically flags suspected pulmonary embolisms (PEs) and immediately notifies physicians.
The Food & Drug Administration has drafted guidelines to help U.S. healthcare better prepare for and respond to events associated with these situations.
Iodinated contrast is most widely used in patients undergoing CT studies for, in descending order, abdominopelvic, chest, head/neck and brain indications.
Computer-aided detection boosted by AI has often proven superior to traditional CAD over the past decade, yet the “new way” has been slow to win broad adoption.
The company says the approval for ablations will allow interventional radiologists to perform these operations with nonlinear steering that facilitates high accuracy and average skin-to-target times under nine minutes.